Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVDLNASDAQ:CADLNASDAQ:SPRYNYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$9.49+4.2%$8.39$6.38▼$17.30$918.05M1.41.24 million shs950,384 shsCADLCandel Therapeutics$5.59+2.6%$5.15$3.79▼$14.60$280.08M-0.921.45 million shs616,174 shsSPRYARS Pharmaceuticals$14.46+0.2%$13.85$7.55▼$18.51$1.42B0.841.27 million shs982,162 shsZYMEZymeworks$11.64+1.8%$11.60$8.21▼$17.70$809.88M1.24597,644 shs298,998 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals+3.94%+3.94%+9.21%+24.21%-40.50%CADLCandel Therapeutics+1.08%+2.95%+5.87%-29.06%-37.19%SPRYARS Pharmaceuticals-1.50%-3.47%0.00%+37.58%+62.84%ZYMEZymeworks-0.26%+0.87%-10.19%-8.71%+37.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVDLAvadel Pharmaceuticals2.2684 of 5 stars3.51.00.00.03.41.70.6CADLCandel Therapeutics2.0236 of 5 stars3.51.00.00.02.51.70.6SPRYARS Pharmaceuticals2.4254 of 5 stars3.60.00.00.02.34.20.6ZYMEZymeworks2.5521 of 5 stars4.50.00.00.02.13.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals 3.00Buy$19.43104.73% UpsideCADLCandel Therapeutics 3.00Buy$21.00275.67% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.00114.38% UpsideZYMEZymeworks 2.90Moderate Buy$21.0080.41% UpsideCurrent Analyst Ratings BreakdownLatest CADL, SPRY, AVDL, and ZYME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025ZYMEZymeworksTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/20/2025ZYMEZymeworksTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/8/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/11/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/9/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.003/14/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.003/11/2025ZYMEZymeworksLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.003/10/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $13.003/7/2025SPRYARS PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$30.003/7/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $19.003/4/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$194.45M4.72N/AN/A$0.98 per share9.68CADLCandel Therapeutics$120K2,333.96N/AN/A$0.44 per share12.70SPRYARS Pharmaceuticals$97.12M14.62N/AN/A$2.40 per share6.03ZYMEZymeworks$93.38M8.67N/AN/A$6.63 per share1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$160.28M-$0.27N/A158.17N/A-52.53%-93.34%-44.77%8/7/2025 (Estimated)CADLCandel Therapeutics-$37.94M-$1.34N/AN/AN/AN/A-629.29%-173.39%8/12/2025 (Estimated)SPRYARS Pharmaceuticals-$54.37M-$0.16N/AN/AN/AN/A-22.56%-21.82%8/5/2025 (Estimated)ZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%7/30/2025 (Estimated)Latest CADL, SPRY, AVDL, and ZYME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SPRYARS Pharmaceuticals-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million3/20/2025Q4 2024SPRYARS Pharmaceuticals-$0.04$0.52+$0.56$0.52$15.46 million$86.58 million3/13/2025Q4 2024CADLCandel Therapeutics-$0.23-$0.40-$0.17-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A2.972.60CADLCandel TherapeuticsN/A1.181.18SPRYARS PharmaceuticalsN/A12.5612.52ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%CADLCandel Therapeutics13.93%SPRYARS Pharmaceuticals68.16%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals4.80%CADLCandel Therapeutics16.60%SPRYARS Pharmaceuticals33.50%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals7096.74 million91.74 millionOptionableCADLCandel Therapeutics6050.10 million18.97 millionOptionableSPRYARS Pharmaceuticals9098.21 million58.21 millionOptionableZYMEZymeworks46069.58 million67.56 millionOptionableCADL, SPRY, AVDL, and ZYME HeadlinesRecent News About These CompaniesZymeworks’ zanidatamab gains approval in China for biliary tract cancerJune 2 at 8:00 PM | msn.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLCJune 2 at 3:14 AM | marketbeat.comVoloridge Investment Management LLC Buys Shares of 43,708 Zymeworks Inc. (NYSE:ZYME)May 31 at 4:10 AM | marketbeat.comRoche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestoneMay 30, 2025 | endpts.comChina's NMPA Approves Zymeworks' Ziihera for HER2-High Biliary Tract CancerMay 30, 2025 | precisionmedicineonline.comZymeworks’ zanidatamab approved in ChinaMay 30, 2025 | thepharmaletter.comZymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To BudgeMay 30, 2025 | msn.comZymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract CancerMay 30, 2025 | globenewswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Holdings in Zymeworks Inc. (NYSE:ZYME)May 30, 2025 | marketbeat.com36,000 Shares in Zymeworks Inc. (NYSE:ZYME) Bought by Polar Asset Management Partners Inc.May 29, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 28, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from AnalystsMay 27, 2025 | americanbankingnews.comWhat is HC Wainwright's Forecast for Zymeworks Q2 Earnings?May 24, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Acquired by Northern Trust CorpMay 23, 2025 | marketbeat.comZymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical ConferencesMay 22, 2025 | globenewswire.comTD Cowen Initiates Coverage on Zymeworks (NYSE:ZYME)May 22, 2025 | marketbeat.comPoint72 Asset Management L.P. Boosts Stock Position in Zymeworks Inc. (NYSE:ZYME)May 22, 2025 | marketbeat.comZymeworks Inc. Presents Promising Preclinical Data for ZW1528, a Novel Bispecific Antibody Targeting IL-4Rα and IL-33 for Respiratory InflammationMay 21, 2025 | nasdaq.comZymeworks Inc. (NYSE:ZYME) Stake Lessened by Vestal Point Capital LPMay 21, 2025 | marketbeat.comTD Securities Initiates Coverage of Zymeworks (ZYME) with Buy RecommendationMay 21, 2025 | msn.comTD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer TherapyMay 21, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCADL, SPRY, AVDL, and ZYME Company DescriptionsAvadel Pharmaceuticals NASDAQ:AVDL$9.49 +0.38 (+4.17%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$9.46 -0.04 (-0.37%) As of 06/2/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Candel Therapeutics NASDAQ:CADL$5.59 +0.14 (+2.57%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$5.56 -0.03 (-0.55%) As of 06/2/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.ARS Pharmaceuticals NASDAQ:SPRY$14.46 +0.03 (+0.21%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$14.46 0.00 (0.00%) As of 06/2/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Zymeworks NYSE:ZYME$11.64 +0.21 (+1.84%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$11.66 +0.01 (+0.13%) As of 06/2/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern 3 Stocks With 3% to 9% Yields Just Raised Dividends Again MarketBeat Week in Review – 05/26 - 05/30 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
